Non-invasive tests to improve cancer detection

Cambridge researchers have developed new methods for detecting and monitoring cancer through simple blood tests, avoiding the need for repeated invasive procedures.  

These tests, developed by the Rosenfeld Group, use circulating tumour DNA (ctDNA), tiny fragments of DNA released by cancer cells into the bloodstream. Analysing ctDNA can reveal the state of the tumour, its location and potentially its weaknesses, which could be used to select the best treatments. 

 The Rosenfeld Group’s work in ctDNA led to the creation of Inivata Ltd., a company specialising in advanced liquid biopsy diagnostics. Liquid biopsies offer a significant advantage by allowing doctors to continuously monitor cancer through blood tests, avoiding the need for more invasive biopsy procedures. 

One of Inivata’s significant achievements is the InVisionFirst®-Lung test for advanced lung cancer. This test helps identify specific mutations, helping to guide clinicians to provide more targeted treatments for patients. This test has been adopted widely and is reimbursed by Medicare in the USA. 

Inivata also developed RaDaR™, a test for detecting cancer recurrence early. In the LUCID-DNA study, RaDaR™ was used to monitor patients with early-stage non-small cell lung cancer (NSCLC) after treatment. The study enrolled 88 patients from Royal Papworth Hospital and Addenbrooke’s Hospital. The research team extracted DNA from tumour samples provided by the patients and sequenced the DNA to find combinations of mutations unique to each patient’s lung cancer. Using this genetic “fingerprint”, Inivata created a blood test that was personalised to the patient’s tumour. 

Researchers found that patients with detectable ctDNA shortly after treatment were more likely to experience a recurrence of their disease. This personalised blood test offers a powerful tool for early detection of residual disease and potential relapse. 

Inivata’s work, based on years of research at the Institute, is making cancer treatment more effective and less invasive. By providing real-time insights into tumour dynamics, these liquid biopsies enable personalised treatment plans and improved outcomes, offering new hope to patients and their families.